Home › Acute Myeloid Leukemia › NCT06906380

A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies

A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1/2 Study and Treated With ARD103 CAR-T Cell Therapies

Who can join

All ages · All sexes

Inclusion Criteria:

* The participant has R/R AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.
* The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.

Exclusion Criteria:

* There are no specific exclusion criteria for this study

About the study

This study will evaluate the long-term safety of ARD103 cellular therapies

What is being tested

• Non interventional study (other)

Sponsor: ARCE Therapeutics, Inc. · Participants: 49 · Started: May 12, 2026

Contact the study team

• ARCE Therapeutics, Inc ARCE · Phone: +886-2-26581868

Official record on ClinicalTrials.gov — NCT06906380

Locations in the U.S.

Conditions

• Acute Myeloid Leukemia
• with Excess of Blasts Refractory Anemia

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.